Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: Findings from the CRUSADE National Quality Improvement Initiative

Pharmacotherapy

Volumn 27, Issue 8, 2007, Pages 1145-1162

  Bottorff, Michael B ^a   Nutescu, Edith A ^b   Spinier, Sarah ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Aspirin; Atherothrombosis; Clopidogrel; Glycoprotein IIb IIIa inhibitors; GP IIb IIIa; Guideline adherence; Non ST segment elevation myocardial infarction; NSTEMI; Quality improvement; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW DENSITY LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

BLEEDING; CONTINUING EDUCATION; DRUG COST; DRUG INDICATION; DRUG USE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; REVIEW; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; GUIDELINE ADHERENCE; HUMANS; MYOCARDIAL INFARCTION; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PROFESSIONAL ROLE; QUALITY ASSURANCE, HEALTH CARE;

EID: 34547544906     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.8.1145     Document Type: Review

References (82)

1. Rogers WJ, Canto JG, Lambrew CF, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the national registry of myocardial infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056-63.
2. Hall MP, Popovic JR. 1998 national hospital discharge survey 316. Vital and health statistics of the Centers for Disease Control and Prevention, June 30, 2000. Available from http://www.cdc.gov/nchs/data/ad/ad316.pdf. Accessed August 3, 2006.
3. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399-408.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002: summary article - a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002;106:1893-900.
5. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S513-48.
6. Alexander KP, Peterson ED, Granger CB, et al. Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global use of strategies to open occluded arteries in acute coronary syndromes trial. J Am Coll Cardiol 1998;32:2023-30.
7. Roe MF, Ohman EM, Pollack CV Jr, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J 2003;146:605-12.
8. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65.
9. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 2002;40:1895-901.
10. Cannon CP. Treatment algorithms and critical pathways for acute coronary syndromes. Semin Vase Med 2003;3:425-32.
11. Grol R. Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. JAMA 2001;286:2578-85.
12. Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA 2001;285:2871-9.
13. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998;279:1358-63.
14. Scott IA, Denaro CP, Hickey AC, et al. Optimising care of acute coronary syndromes in three Australian hospitals. Int J Qual Health Care 2004;16:275-84.
15. The Cooperative Cardiovascular Project Best Practices Working Group. Improving care for acute myocardial infarction: experience from the cooperative cardiovascular project. Jt CommJ Qual Improv 1998;24:480-90.
16. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
17. O'Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005;39:1423-7.
18. Chapman NR, Fotis MA, Yarnold PR, Gheorghiade M. Pharmacist interventions to improve the management of coronary artery disease. Am J Health-Syst Pharm 2004;61:2672-8.
19. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110:588-636. (Erratum in Circulation 2005;111:2013-14.)
20. Fonarow GC, Gawlinski A, Moughrabi S, Fillisch JH. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol 2001;87:819-22.
21. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004;164:203-9.
22. McCarthy M. U.S. heart-guidelines strategy makes promising start. Lancet 2001;358:1618.
23. American Heart Association. Get with the guidelines program, 2006. Available from http://www.americanheart.org/presenter.jhtml?identifier=1165. Accessed June 15, 2006.
24. Fonarow GC, Gheorghiade M, Abraham WF. Importance of in-hospital initiation of evidence-based medical therapies for heart failure: a review. Am J Cardiol 2004;94:1155-60.
25. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the guidelines applied in practice (GAP) initiative. JAMA 2002;287:1269-76.
26. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's guidelines applied in practice (GAP) projects in Michigan. J Am Coll Cardiol 2005;46:1242-8.
27. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on performance measures (writing committee to develop performance measures on ST-elevation and non-ST-elevation myocardial infarction). Circulation 2006,113:732-61.
28. Joint Commission on Accreditation of Healthcare Organizations. Acute myocardial infarction national quality measures. Available from http://www.jointcommission.org/NR/rdonlyres/42AE880A-7942-4A7B-B63E- 6D8637264A54/0/2a_AMl_List.pdf. Accessed June 23, 2006.
29. Hoekstra JW, Pollack CV Jr, Roe MT, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad EmergMed 2002;9:1146-55.
30. Duke Clinical Research Institute. The CRUSADE national quality improvement initiative, 2006 2nd quarter results. Available from http://www.crusadeqi.com/Main/HomePage.shtml. Accessed June 15, 2006.
31. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
32. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
33. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy trial. N Engl J Med 1998;339:436-43.
34. Antman EM. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Am HeartJ 2003;146:S18-22.
35. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
36. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
37. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
38. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-63.
39. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without SF-segment elevation. N Engl J Med 2001;345:494-502.
40. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004;109:745-9.
41. Bhatt DL, Roe MF, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE quality improvement initiative. JAMA 2004;292:2096-104.
42. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines) national quality improvement initiative. J Am Coll Cardiol 2005;45:832-7.
43. Calvin JE, Roe MT, Chen AY. The effect of insurance type on use of evidence-based therapies in high-risk acute coronary syndromes: results from CRUSADE [abstract]. Circulation 2004;109:29.
44. Cohen MG, Roe MT, Sonel AF. Hispanic patients with non-ST-segment elevation acute coronary syndromes receive less evidence-based care and are less frequently managed by a cardiologist: results from CRUSADE [abstract]. Circulation 2004;109:28-9.
45. Goswami R, Chen AY, Riba AL. Sub-optimal care for non-ST-segment elevation acute coronary syndrome patients presenting with congestive heart failure is associated with higher mortality [abstract]. Circulation 2004;110:518.
46. Han JH, Chandra A, Roe MT. Relationship of renal insufficiency to the quality of non-ST-segment elevation acute coronary syndromes care and outcomes: results from the CRUSADE initiative [abstract]. Circulation 2004;110:784.
47. Hoekstra JW, Roe MT, Peterson ED, et al. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med 2005;12:431-8.
48. Ohman EM, Kandzari D, Menon V. Underutilization of revascularization in early cardiogenic shock among patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE initiative [abstract]. Circulation 2004;110:410.
49. Sonel AF, Good CB, Mulgund J, et al. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines?). Circulation 2005;111:1225-32.
50. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006;166:806-11.
51. Dyke CK, Roe MT, Cohen DJ. Patients with non-ST-segment elevation acute coronary syndromes receive less aggressive discharge care after bypass surgery versus percutaneous coronary intervention [abstract]. Circulation 2004;110:420.
52. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004;110:1202-8.
53. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
54. Peterson ED, Pollack CV Jr, Roe MT, et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the national registry of myocardial infarction 4. J Am Coll Cardiol 2003;42:45-53.
55. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006;47:522-8.
56. Roe MT, Christenson RH, Ohman EM, et al. A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. Am Heart J 2003;146:993-8.
57. Giugliano RP, Newby LK, Harrington RA, et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome: study design and rationale. Am Heart J 2005;149:994-1002.
58. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8.
59. Gibler WB, Peterson ED, Roe MT. Early treatment for non-ST-segment elevation acute coronary syndromes is associated with appropriate discharge care: the CRUSADE experience [abstract]. J Am Coll Cardiol 2005;45:5A.
60. Peterson ED, Roe MT, Li Y. Influence of physician specialty on care and outcomes of acute coronary syndrome patients: results from CRUSADE [abstract]. J Am Coll Cardiol 2003;41:534A.
61. Cairns CB, Mulgund J, Roe MT. Do rural hospitals provide timely and effective care for patients with non-ST-segment elevation acute coronary syndromes? Circulation 2005;111:e310-59.
62. Patel MR, Chen AY, Roe MT, et al. A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med 2007;120:40-6.
63. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16.
64. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
65. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
66. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 2000;36:970-1062.
67. Kandzari DE, Roe MT, Chen AY, et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am HeartJ 2005;149:474-81.
68. Menon V, Peterson ED, Roe MT. Regional variation in the treatment and outcomes of patients with unstable angina/STEMI [abstract]. Circulation 2004;109(suppl):32.
69. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006;295:1912-20.
70. Peterson ED, Chen AY, Kontos MC, et al. Associating changes in hospital non-ST-segment elevation acute coronary syndromes guidelines adherence with changes in patient outcomes: results from CRUSADE [abstract]. Circulation 2004;110:785.
71. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in U.S. ambulatory care for the secondary and primary prevention of cardiovascular disease [online exclusive article]. PLoS Med 2005;2:e353. Available from http://dx.doi.org/ 10.1371/journal.pmed.0020353.
72. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
73. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
74. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110:588-636.
75. Bosanquet N, Jonsson B, Fox KA. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein Ilb/IIIa inhibitors: in the management of acute coronary syndromes. Pharmacoeconomics 2003;21:1135-52.
76. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-71.
77. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes: estimating the economic implications. Pharmacoeconomics 2001;19:41-55.
78. Karnon J, Bakhai A, Brennan A, et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol 2006;109:307-16.
79. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838-45.
80. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9.
81. Cowper PA, Udayakumar K, Sketch MH Jr, Peterson ED. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 2005;45:369-76. (Erratum inj Am Coll Cardiol 2005;45:1912.)
82. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost-effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6.